INTRODUCTION
============

Primases, essential enzymes in all domains of life, synthesize primers for DNA replication ([@gks1292-B1]). Bacterial primases (DnaG) are highly conserved, and they are distinct from their eukaryotic and archaeal counterparts ([@gks1292-B2]). Therefore, DnaG is a novel and attractive antibacterial drug target. By using single-stranded DNA (ssDNA) as a template, DnaG synthesizes short (\<30-nt) RNA primers that are then extended by the replicative DNA polymerase (Pol III) in the process of chromosomal DNA replication ([@gks1292-B16]). Because DnaG is an inefficient and weakly processive RNA polymerase ([@gks1292-B17]), traditional priming activity assays ([@gks1292-B23],[@gks1292-B24]), including the only reported assay used in high-throughput screening (HTS) ([@gks1292-B25]), use radioactively labelled nucleotide triphosphates for detection of the priming reaction products. Despite the weak activity of DnaG, such priming activity assays with primase alone have been reported ([@gks1292-B18],[@gks1292-B21],[@gks1292-B22]). To boost the primase activity for its detection, other accessory DNA replication proteins, such as ssDNA binding protein or DnaB helicase, have been commonly used. The only previously reported non-radioactive primase activity assay potentially applicable to HTS is a fluorometric assay based on the increase of fluorescence of PicoGreen dye with RNA--DNA duplex formation ([@gks1292-B26]). This assay is expected to work efficiently when the primers made in the assay are long (\>6 nt), so that they form a stable duplex with DNA, needed for robust PicoGreen fluorescence enhancement. A shortcoming of fluorometric assays in their use in HTS is a possible interference of aromatic or non-polar compounds with the signal because of their interactions with the fluorescent label.

HTS using radioactivity demands rigorous safety measures, generates large amounts of liquid waste and is costly. For these reasons, use of radioactivity in most academic HTS facilities is not feasible. A non-radioactive and quantitative primase assay, as the one we have developed in this study, is highly desirable for HTS as well as for a more facile characterization of primases and other inefficient nucleic acid polymerases.

To develop the primase assay, we chose the previously uncharacterized DnaG from *Mycobacterium tuberculosis* (*Mtb* DnaG), the deadliest bacterial pathogen. A highly optimized purification procedure for *Mtb* DnaG and identification of conditions that maximize its steady-state nucleotidyl transferase activity reported here enabled us to develop a novel robust primase activity assay. In this assay, we use another essential bacterial protein, inorganic pyrophosphatase (PPiase) ([@gks1292-B27]) as a coupled enzyme. PPiase selectively cleaves pyrophosphate (PP~i~) into two phosphates (P~i~) and does not hydrolyse nucleotide triphosphates, thus allowing us to monitor PP~i~ release through detection of P~i~ ([@gks1292-B28],[@gks1292-B29]). *In vivo*, the cleavage of PP~i~ by PPiase is used to drive otherwise reversible nucleotide transfer reactions, in which a nucleotide monophosphate is transferred from a nucleotide triphosphate (NTP) onto a substrate with the release of PP~i~. These types of reactions include chromosomal DNA synthesis as well as the fatty acid adenylation, a critical biochemical step in fatty acid metabolism. In fact, inorganic pyrophosphatases from yeast and *Escherichia coli* were previously used in coupled assays with other enzymes, such as protein prenyltransferases ([@gks1292-B30]), adenylate cyclase ([@gks1292-B31]), acetyl-CoA synthetase ([@gks1292-B32]) and aminoacyl-tRNA synthetase ([@gks1292-B33]). In our assay, we use PPiase from *Mtb* (162 amino acid residues), which shares a modest (30%) amino acid residue sequence identity to its human counterpart, PPA1 (289 residues). The considerable divergence between PPA1 and *Mtb* PPiase, including residue differences in the active sites of these two enzymes ([@gks1292-B34]), implies a possibility of discovering an inhibitor selective for *Mtb* PPiase.

Conceptually novel anti-tuberculosis drugs are acutely needed in clinics because of the alarming spread of multidrug-resistant strains of *Mtb*. Herein, we report the development of a new coupled primase--pyrophosphatase assay that exploits two novel attractive bacterial targets, *Mtb* DnaG and *Mtb* PPiase, for inhibitor discovery.

MATERIALS AND METHODS
=====================

Cloning and purification of *Mtb* DnaG
--------------------------------------

The primase gene *dnaG* (locus tag: Rv2343c) was amplified by polymerase chain reaction from *Mtb* H37Rv genomic DNA (BEI Resources, NIAID, NR-14865) by using primers (5′-AGTTAGCACATATGTCCGGCCGGATCTCCG-3′) and (5′-CCGCTCGAGTCACGCGGTGAGATCG-3′) and cloned between NdeI and XhoI sites of a modified pET19b vector ([@gks1292-B35]), encoding an N-terminal decahistidine tag separated from the recombinant protein by a PreScission protease (GE Healthcare, Piscataway, NJ, USA) cleavage site. The construct expressing *Mtb* DnaG E268Q was generated by mutagenesis of the aforementioned construct with a QuikChange Kit (Qiagen, Valencia, CA, USA) by using primers 5′-CATCAGGCCGTCGTCGTCCAGGGCTACACCGATGTCATG-3′ and 5′-CA TGACATCGGTGTAGCCCTGGACGACGACGGCCTGATG-3′. The wild-type and the mutant proteins were expressed and purified analogously. Protein expression was carried out in BL21 (DE3) cells cultured in LB broth. The culture was induced with 0.5 mM of IPTG at an attenuance of 0.2 and then incubated for 16 h at 18°C. All purification steps were carried out at 4°C. The cell pellet from a 4 l culture was suspended in 100 ml of buffer A \[40 mM Tris--HCl pH 8.0, 600 mM of NaCl, 10% of glycerol, 1 mM of PMSF, 0.5 mM of adenosine triphosphate (ATP), 2 mM of MgCl~2~ and 2 mM of β-mercaptoethanol\] containing two tablets of complete ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA). The cells were disrupted by sonication on ice and clarified by centrifugation at 38 000*g* for 60 min. The supernatant was filtered through a 0.45 µm Millex-HV PVDF filter (Millipore, Billerica, MA, USA) and applied to a 5 ml Ni-IMAC HisTrap FF column (GE Healthcare) equilibrated with buffer A. The column was washed with 120 ml of buffer A containing 50 mM imidazole, and then protein was eluted with 11 ml of buffer A containing 500 mM imidazole. The eluate was adjusted to NaCl of 200 mM, with buffer A prepared without NaCl and digested overnight at 4°C with PreScission protease. The digested protein was purified on a size-exclusion S-200 column (GE Healthcare) equilibrated in buffer B (40 mM Tris--HCl pH 8.0, 600 mM of NaCl, 10% of glycerol, 0.25 mM of ATP, 2 mM of MgCl~2~ and 2 mM of β-mercaptoethanol), and the protein-containing fractions were pooled and concentrated using an Amicon Ultra-15 centrifugal filter device (Millipore) to 5 mg/ml. The enzyme was stored on ice for all assays. The recombinant untagged DnaG was highly homogeneous (Coomassie blue staining indicated \>95% purity) and remained stable and active, while on ice, for 2 weeks. One hour before the assays, the storage buffer was exchanged by MicroSpin G-25 columns (GE Healthcare) into buffer C (40 mM of HEPES--NaOH pH 7.5, 600 mM of NaCl, 10% of glycerol, 2 mM of MgCl~2~, 2 mM of β-mercaptoethanol and 0.1 of mM ATP). The presence of ATP in the protein buffer results in 10 µM ATP in the reaction mixture. This low concentration of ATP is negligible, as it is below *K*~m~ for ATPases and other ATP-interacting enzymes, including *Mtb* DnaG. Partial degradation of such a small amount of ATP, even if it occurred, would be below or at the detection limit of our assay.

Purification of *Mtb* PPiase
----------------------------

The pJ411 vector (DNA2.0, Menlo Park, CA, USA) encoding *Mtb* PPiase bearing an N-terminal hexahistidine-tag was a generous gift from Dr Luiz Pedro Carvalho. *Mtb* PPiase was expressed similarly to *Mtb* DnaG. All purification steps were carried out at 4°C. The cell pellet was resuspended in 20 mM of TEA buffer pH 7.8. The cells were disrupted sonication and clarified by centrifugation at 25 000*g* for 30 min. The supernatant was applied to a 5 ml Ni-IMAC HisTrap FF column (GE Healthcare) equilibrated with buffer A (20 mM TEA pH 7.8, 50 mM of imidazole and 300 mM of NaCl). The column was washed with 220 ml of buffer A, and protein was eluted with a linear gradient of 50--500 mM of imidazole in buffer A (570 ml). The fractions containing *Mtb* PPiase were pooled, concentrated and passed through a size-exclusion S-200 column (GE Healthcare) equilibrated in 40 mM of Tris--HCl pH 8.0, 100 mM of NaCl. The fractions containing protein were pooled and concentrated using an Amicon Ultra-15 centrifugal filter device (Millipore) to 750 µM. The recombinant His-tagged *Mtb* PPiase was highly homogeneous (Coomassie blue staining indicated \>98% purity) and stable at 4°C for 6 months.

Coupled colorimetric primase--pyrophosphatase assay (optimization of conditions)
--------------------------------------------------------------------------------

In all coupled primase--pyrophosphatase assays that were carried out during the optimization phase to determine DNA template (sequence and length), divalent metal type and concentration, buffer type and pH and in time course experiments, we mixed DNA (Integrated DNA Technologies, Coralville, IA, USA), buffer, NTP (Promega, Madison, WI, USA) and pyrophosphatase on ice and then added *Mtb* DnaG, so that the reagent mixture is at twice the intended concentration of all reagents. The mixture was then diluted two-fold with water to give the final concentration of *Mtb* DnaG (0.7 µM or as specified) DNA (1.25 µM or as specified), NTP (110 µM or as specified), NaCl (50 mM), KGlu (150 mM), buffer (20 mM of CAPS pH 8.8 or as specified) and divalent metals (2 mM of Mn^2+^ and 1 mM of Mg^2+^ or as specified). *Mtb* DnaG alone is prone to severe aggregation and rapidly becomes inactive at salt concentrations \<275 mM. However, in the presence of DNA and nucleotides, *Mtb* DnaG maintains its solubility and activity. The reaction mixture was incubated at room temperature (22°C) for 30 min. In the assay optimization experiments, inorganic pyrophosphatase from *Saccharomyces cerevisiae* (Sigma-Aldrich, St. Louis, MO, USA) was used in a three-fold excess of the minimal concentration needed for complete PP~i~ cleavage (as determined experimentally for each enzyme stock). The yeast enzyme was replaced by *Mtb* PPiase in the HTS and in the mode of inhibition studies. The P~i~ formed as a consequence of breakdown of the released PP~i~ was quantitated using procedures adapted from earlier studies ([@gks1292-B36]). In brief, 150 µl of the malachite green reagent (MGR; a 2:1:1:2 mixture of 0.0812% malachite green, 2.32% w/v polyvinyl alcohol, 5.72% in 6 M of HCl ammonium molybdate and water) was added to 30 µl reactions and followed by addition of 15 µl of 34% sodium citrate after 1 min. After allowing colour to develop for 30 min, absorbance at 620 nm was measured with a Biotek Synergy H1 plate reader (Biotek, Winooski, VT, USA). In all coupled primase--pyrophosphatase assays, we calibrated the absorbance at 620 nm to the concentration of P~i~ (twice that of PP~i~) by using sodium phosphate and verified the linearity of the signal in the experimental range (the signal was linear up to Abs = 1.5). For the assay optimization and inhibitor characterization, we used flat-bottom 96-well clear polystyrene plates (Fisher Scientific, Pittsburgh, PA, USA).

Primer synthesis assay
----------------------

Primer synthesis reactions to observe the radiolabelled RNA products were carried out under conditions similar to those determined in the course of the optimization of conditions by the coupled primase--pyrophosphatase assay. More specifically, the reactions were carried out in buffer containing DNA (1 µM; the sequences are specified in the text), NTP (100 µM) in 20 mM of CAPS pH 8.8, 150 mM of KGlu containing divalents (Mn^2+^ or Mg^2+^), DTT (1 mM) and 110 nM of α--^32^P-GTP. The products were extracted with phenol and run in a 12% urea--polyacrylamide gel. The gels were exposed to phosphorimager plates and read in a Typhoon phosphorimager system (GE Healthcare).

High-throughput screening assay
-------------------------------

For its performance in HTS, we adapted the assay so that it can sustain the manipulations at room temperature for 4--6 h without any significant deleterious effects on the protein or other reagents. Fifty nanomolars of *Mtb* PPiase, instead of yeast PPiase, was used in the HTS and inhibitor characterization. To minimize the number of injections and error in dispensing reagents using liquid handling robotics, we revised the assay protocols. Small molecule compounds were dispensed into 384-well flat bottom, non-binding surface, polystyrene plates (Corning Incorporated, Corning, NY, USA) from the compound library plates with a Biomek FX robot (Beckman Coulter, Brea, CA, USA) with 200 nl of inhibitors (to obtain the final concentration in the reaction of 13 µM). Twenty microlitres of the NTP mix (with 2 mM of β-mercaptoethanol) in water was then added to all wells. EDTA at the final concentration of 30 mM was added to the last two columns of wells as a positive inhibition control. Finally, a 10 µl mixture of DNA, *Mtb* PPiase and *Mtb* DnaG in the appropriate buffer (at three-fold higher concentrations of all reaction and buffer components than their final concentrations) was added. After 30 min incubation at room temperature, 30 µl of the MGR was added followed by 10 µl of 10% sodium citrate, and plates were shaken briefly. Absorbance at 620 nm was read in 30 min with a PHERAstar plate reader (BMG Labtech, Cary, NC, USA). This assay was used to screen a library of 2556 small molecules comprising 2000 food and drug administration-approved drugs (Spectrum Chemicals, New Brunswick, NJ, USA), 450 molecules that have been used in human therapy (NIH Clinical Collection) and 106 kinase inhibitors (Enzo Life Sciences, Farmingdale, NY, USA).

The *Z′* score was calculated for the pilot 384-well assay where DMSO was delivered without the small molecules, by using the following equation ([@gks1292-B37]): where Av(pos) and SD(pos) are the signal (absorbance) and its standard deviation for the positive controls (EDTA-containing reactions), and Av(neg) and SD(neg) are the respective values for negative controls (DMSO-containing reactions).

Dose--response assays
---------------------

For the mode of inhibition studies, the reactions were carried out under conditions similar to those used in the HTS, except the volumes of the colour reagents were slightly modified to adapt it to the 96-well plate and to further increase the stability and consistency of the colour formation. In these assays, 90 µl of MGR was added to a 30 µl reaction mixture followed by 30 µl of 10% sodium citrate.

Reactions were carried out with \[*Mtb* DnaG\] = 0.5 µM, \[DNA\] = 1.25 µM, \[NTP\] = 110 µM at different concentrations of inhibitors, as specified in the text. Relative activities were calculated by dividing the concentrations of PP~i~ released in the priming reactions in the presence of inhibitors by that released in its absence. The following dose--response equation was used to fit these data with SigmaPlot 9.0 (SysStat Software, San Jose, CA, USA), with *IC*~50~ and the Hill coefficient *n* as the fitting parameters:

Analysis of mode of inhibition assays
-------------------------------------

The assays were performed with *Mtb* DnaG (0.5 µM) and *Mtb* PPiase (50 nM) in the same reaction buffer as that used in the HTS assays. The steady-state rate of PP~i~ release was calculated based on measurements of the concentration of released PP~i~ in 20-min reactions, as described earlier in the text. Two sets of reactions were run: (i) at constant \[DNA\] = 1.25 µM at different concentrations of NTP (31.25, 62.5, 125, 250 and 500 µM) and (ii) at constant \[NTP\] = 110 µM at different concentrations of DNA (0.19, 0.38, 0.75 and 1.5 µM). We observed inhibition of P~i~ generation by NTP and DNA at higher NTP and DNA concentrations beyond the aforementioned ranges; therefore, they were not used in this analysis. For each pair of DNA and NTP concentrations, different concentrations of the inhibitors (suramin and doxorubicin) were used (0, 1.25, 2.5, 5, 10, 20 and 40 µM). As a simplifying approximation, to analyse the data, we used an ordered sequential rapid equilibrium mechanism of RNA synthesis by DnaG, in which DNA binds free DnaG first, followed by binding of the first NTP and subsequent binding and incorporation of an average of *m* nucleotides (releasing *m* PPi molecules) and dissociation of DnaG from DNA:

Here, *K*~DNA~ and *K*~NTP~ are equilibrium constants for binding primed DNA and NTP, respectively, both defined for the dissociation direction. This mechanism assumes that the concentration of NTP affects only initiation of primer synthesis. If the first NTP incorporation is slow (primer nucleation) relative to the *m*-1 subsequent incorporation steps (elongation), then *k*~cat~ is the catalytic rate constant of the slow nucleation step.

Because the data exhibit competitive inhibition with respect to both DNA and NTP and the inhibitor:target stoichiometry higher than 1:1 (model-independent observations), we considered the simplest competitive inhibition mechanism, in which an inhibitor (I) can bind non-cooperatively to *n* binding sites on *Mtb* DnaG:

We designate as *K*~i~ an intrinsic equilibrium constant for binding of an inhibitor molecule to a site on DnaG, defined for the dissociation direction. This mechanism yields the following equation for the steady-state rate of PP~i~ release (*V*) in large excess of NTP and inhibitor, but not DNA, over *Mtb* DnaG:

Because one nucleation event leads to release of *m* PPi molecules, *k*~cat,app~ = *mk*~cat~. The concentrations of free *Mtb* DnaG, \[DnaG\] and all DNA species not bound to DnaG, \[DNA\], are obtained from the conservation of material equations for DnaG and DNA and from the aforementioned equilibria as: where

Here, \[DnaG\]~T~ and \[DNA\]~T~ are the total concentrations of *Mtb* DnaG and DNA in the reaction, respectively. This rate law was globally fit to all the data collected for each inhibitor by using non-linear regression with SigmaPlot 9.0, with *k*~cat,app~, *K*~DNA~, *K*~NTP~ and *K*~i~ as fitting parameters for different fixed integer values of *n*. A satisfactory fit was not obtained for *n* = 1 or *n* = 2 for either suramin or doxorubicin, consistent with the model-independent dose--response analysis. For suramin, the data were well fit for *n* = 4, whereas for doxorubicin, an equally good fit was produced for *n* = 3, yielding the best fit parameter values and the theoretical curves generated by using these as presented in the 'Results' section. The data could be fit equally well by a more complex model, in which the inhibitors bind *Mtb* DnaG with high cooperativity, with *n* = 3 and *n* = 2 for suramin and doxorubicin, respectively. However, because the cooperative binding model contains too many fitting parameters to be resolved by the data, and because it lacks support by other experimental evidence, it is not presented here in further detail.

DNA-binding assay
-----------------

DNA affinity of *Mtb* DnaG for ssDNA was measured at the conditions of the priming activity assays, either in the absence of NTPs or in the presence of all four NTPs, at \[NTP\] = 110 µM. We used a single-stranded 28-mer ssDNA: 5′-CCGAATCAGTCCGACGACGCATCAGCAC-3′, labelled at the 5′-end with 6-carboxyfluorescein (6FAM; Integrated DNA Technologies, Coralville, IA, USA). Titrations were set-up at the constant concentration of ssDNA of 20 nM at different concentrations of *Mtb* DnaG in separate 50 µl reaction mixtures and were equilibrated for 20 min at 22°C. Fluorescence anisotropy was monitored by a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA), set at the excitation and emission wavelengths of 495 and 520 nm, respectively. To obtain equilibrium protein-DNA binding constant *K*~d~, non-linear least-squares regression data fitting to the equilibrium 1:1 binding isotherm was performed with SigmaPlot 9.0 as previously described ([@gks1292-B38]). No significant difference was observed between titrations in the presence or absence of NTPs; therefore, these data were averaged together.

RESULTS
=======

Purification of *Mtb* DnaG
--------------------------

Expression and purification of *Mtb* DnaG have not been previously reported. Initially, we tested a variety of expression and purification protocols previously reported for other DnaG proteins; these efforts yielded inactive aggregated protein. During the extensive optimization of the purification procedure, we found that ATP (0.25 mM), NaCl (600 mM) and glycerol (∼10%) all need to be present during all purification steps to prevent *Mtb* DnaG from aggregation. As a result, we obtained pure and active *Mtb* DnaG. The purified protein ([Figure 1](#gks1292-F1){ref-type="fig"}A) is homogeneous and monomeric as judged by S-200 size-exclusion chromatography ([Figure 1](#gks1292-F1){ref-type="fig"}B). Figure 1.Purified *Mtb* DnaG. (**A**) A Coomassie-stained 12% sodium dodecyl sulphate--polyacrylamide gel electrophoresis of the purified *Mtb* DnaG showing its homogeneity. (**B**) The S-200 size-exclusion chromatogram of *Mtb* DnaG demonstrating its monomeric state.

Development of a novel non-radioactive coupled primase--phosphatase assay
-------------------------------------------------------------------------

Primase activity has been historically monitored by visualization and quantification of radiolabelled RNA primers on a denaturing gel. We sought to develop a novel activity assay that would be robust (even at room temperature), would not require the use of radioactivity and would not require accessory factors, such as ssDNA-binding protein or DnaB helicase, which have been used previously to enhance primase activity. Such an assay would be highly suitable for high-throughput applications.

We developed a colorimetric coupled primase--pyrophosphatase assay satisfying these requirements ([Figure 2](#gks1292-F2){ref-type="fig"}). Inorganic pyrophosphatase (PPiase, type I) is used to cleave the pyrophosphate (PP~i~) liberated in the priming reaction into phosphate (P~i~). To measure the P~i~ concentration, we use the MGR ([@gks1292-B36]), whose absorbance at 620 nm increases with increasing concentration of P~i~, changing its colour from yellow to green. PPiase cleaves exclusively PP~i~ and does not exhibit any cleavage activity on NTP ([@gks1292-B29]), a property that we also confirmed for yeast and *Mtb* PPiases. The concentration of PPiase was chosen to be three-fold higher than the minimum concentration required for cleavage of all released PP~i~. Figure 2.A schematic of the coupled colorimetric primase (DnaG)--pyrophosphatase (PPiase) assay.

By monitoring synthesis of radiolabelled primers, we directly established that at the minimal conditions of our novel coupled assay, *Mtb* DnaG displays robust Mn^2+^-dependent primer synthesis activity and has no detectable activity in Mg^2+^ ([Figure 3](#gks1292-F3){ref-type="fig"}). This activity is not highly processive, as evidenced by several short (\<10 nt) products of different lengths, which is also observed with other primases ([@gks1292-B21]). Because *Mtb* DnaG is an intrinsically inefficient polymerase, in developing the new assay, it was important to minimize any unwanted phosphate-borne signal from spurious ATPase activity that may be present in the protein preparations. Therefore, to avoid possible interference from ATPases, we designed a new DNA template ([Figure 4](#gks1292-F4){ref-type="fig"}, top inset). This template does not contain thymidine nucleotides in its 5′-half, so that ATP is not needed for the synthesis of complementary RNA; as a result, we could omit ATP in the reaction. Indeed, we obtained a robust DNA-dependent signal from the primer synthesis activity by *Mtb* DnaG in this reaction set-up with only CTP, GTP and UTP ([Figure 4](#gks1292-F4){ref-type="fig"}). An *Mtb* DnaG point mutant E268Q of a conserved divalent metal-coordinating residue ([@gks1292-B39]) that is absolutely required for catalysis ([@gks1292-B21],[@gks1292-B40]) was used as a control to ensure that the observed signal resulted specifically from the primer synthesis activity of *Mtb* DnaG. No signal was observed without the inorganic pyrophosphatase. We then performed the assay with a variety of divalent metal salts ([Figure 5](#gks1292-F5){ref-type="fig"}). The results confirmed the lack of detectable activity with Mg^2+^ and demonstrated that Mn^2+^ was the only divalent metal that supported robust activity among the seven metals tested. Mn^2+^ was previously reported to increase DnaG activity without significantly affecting other properties of DnaG ([@gks1292-B21]). In a recently determined crystal structure of the catalytic core of *Staphylococcus aureus* DnaG in complex with nucleotides, a catalytic Mn^2+^ ion was shown to be interchangeable with Mg^2+^ ([@gks1292-B39]). Figure 3.Synthesis of radiolabelled RNA primers by *Mtb* DnaG and its inhibition by 10 µM doxorubicin (D) and suramin (S). Phosphorimager analysis of a 12% of urea--polyacrylamide gel electrophoresis showing RNA products of the priming reaction. The priming reaction was performed with 1 mM of Mg^2+^, 2 mM of Mn^2+^ and both on a 38-mer ssDNA template 5′-CTGGTGGGCCCAAACTTGATGCTCTAATACCGACGCGT-3′ in the presence of a mixture of the four nucleotides containing α-^32^P-GTP. Figure 4.Representative coupled primase--pyrophosphatase reactions (a 30-min time point) with wild-type (wt) and E268Q mutant of *Mtb* DnaG. Figure 5.Activity of *Mtb* DnaG in the presence of different divalent metals, at 2 mM. The grey bars indicate the absorbance at time 0 in the reaction.

Optimization of assay conditions
--------------------------------

The colorimetric primase--pyrophosphatase assay provides a quantitative measure of kinetics of NTP incorporation into growing RNA by measuring PP~i~ release ([Figure 6](#gks1292-F6){ref-type="fig"}A). At these conditions (\[*Mtb* DnaG\] = 0.7 µM, \[DNA\] = 1.25 µM, \[NTP (CTP, GTP, UTP)\] = 110 µM each), the linear steady-state accumulation of PP~i~ persists until ∼30 min from the start of the reaction, after which the signal starts to reach the plateau, likely because of accumulation of stable RNA--DNA duplexes or because of protein aggregation. Therefore, to obtain a robust signal in the steady-state measurements, a reaction time of 20--30 min (as specified) was chosen for further measurements. To find conditions that maximize the primer synthesis activity in our assay, we tested a variety of solution parameters. When measured as a function of the concentration of the divalent metal of choice, Mn^2+^, *Mtb* DnaG exhibited a maximum activity near 2 mM of Mn^2+^ ([Figure 6](#gks1292-F6){ref-type="fig"}B). Mg^2+^ (1 mM) is used in the reaction to ensure robust activity of PPiase, which is not highly active in Mn^2+^ alone ([@gks1292-B34]). Potassium glutamate (KGlu) was chosen for the assay, as it is the major electrolyte *in vivo* ([@gks1292-B41]), and it significantly enhances protein--DNA interactions *in vitro* ([@gks1292-B42]). The activity was optimal in the physiological KGlu concentration range, 150--200 mM ([Figure 6](#gks1292-F6){ref-type="fig"}C). The primase was active in a variety of buffers and with pH values in the range 6.0--9.0 ([Figure 6](#gks1292-F6){ref-type="fig"}D); 20 mM of CAPS pH 8.8 was chosen, as it supported the highest activity of *Mtb* DnaG among the tested buffers and pHs. Figure 6.Optimization of conditions of the primase--pyrophosphatase assay. (**A**) A representative time course of the priming reaction, monitored by quantifying released PP~i~. (**B**) Dependence of activity of *Mtb* DnaG on the concentration of MnCl~2~. (**C**) Activity of *Mtb* DnaG as a function of the concentration of potassium glutamate. (**D**) Activity of *Mtb* DnaG in a variety of buffers (20 mM) at different pH in the range 6.0--9.0. The grey bars indicate the absorbance at time 0 in the reaction. (**E**) The steady-state rate of PP~i~ release during primer synthesis by *Mtb* DnaG as a function of DNA concentration. The reactions were carried out for 30 min at \[*Mtb* DnaG\] = 0.7 µM, \[NTP\] = 110 µM. (**F**) The steady-state rate of PP~i~ release by *Mtb* DnaG as a function of NTP concentration. The reactions were carried out for 30 min at \[*Mtb* DnaG\] = 0.7 µM, \[DNA\] = 1.25 µM.

The observed steady-state rate of PP~i~ release measured as a function of DNA concentration at \[NTP\] = 110 µM displayed a saturating behaviour indicative of tight binding of *Mtb* DnaG to DNA (a nearly linear increase of activity until half-saturation), with *K*~m,obs~ \< 0.3 µM and *V*~max,obs~ = 1.16 ± 0.06 µM/min ([Figure 6](#gks1292-F6){ref-type="fig"}E); the subscript 'obs' is used here to reflect the dependence of these parameters on the concentration of NTP. Only an upper bound on *K*~m,obs~ (\<0.3 µM) can be determined from this titration, because \[*Mtb* DnaG\] \> *K*~m~. Based on this dependence, we used \[DNA\] = 1.25 µM for HTS and inhibitor characterization, to maximize the signal and to ensure the sensitivity of the assay to potential inhibition. We observed a hyperbolic (Michaelis--Menten) saturation behaviour of the rate of PP~i~ release as a function of NTP concentration (at \[DNA\] = 1.25 µM; [Figure 6](#gks1292-F6){ref-type="fig"}F), yielding *K*~m,obs~ = 177 ± 7 µM and *V*~max,obs~ = 2.85 ± 0.04 µM/min. Note that the *V*~max,obs~ value obtained in this assay is higher than that in the previous assay because \[DNA\] = 1.25 µM is saturating, whereas \[NTP\] = 110 µM is not. At \[NTP\] near 100 µM, a robust signal was achieved. Because less than a two-fold increase in signal required using five-fold higher concentrations of expensive high-purity NTPs in material-consuming HTS, we chose \[NTP\] = 110 µM for HTS.

High-throughput screening of 2560 compounds to discover inhibitors of *Mtb* DnaG and *Mtb* PPiase by the primase--pyrophosphatase assay
---------------------------------------------------------------------------------------------------------------------------------------

We adapted the assay to the 384-well format for its use in HTS of libraries of small molecules. To evaluate the suitability of the assay for HTS, we performed a control assay in a 384-well plate where DMSO solution (without small molecule compounds) was delivered into the reactions in all but 32 wells, and EDTA (at final concentration of 30 mM) was added in the remaining 32 wells as a positive inhibition control ([Figure 7](#gks1292-F7){ref-type="fig"}A). The inhibition by EDTA (manifested by the absence of the green colour of the MGR) was clearly distinguishable by the naked eye. The absorbance measurements in this control assay yielded a *Z*′ score of 0.7, indicating that the assay is robust and suitable for HTS ([@gks1292-B37]). Figure 7.High-throughput coupled *Mtb* DnaG-*Mtb* PPiase assays. (**A**) A control assay used to calculate the *Z′* score. The last two columns of wells contain 30 mM of EDTA, used as a positive inhibition control in the HTS. (**B**) The scatterplot of the pilot assay with 2560 diverse compounds. Red squares indicate full inhibition by 30 mM of EDTA (as in panel A). Compounds that do not exhibit inhibitory properties (serving as negative controls) are shown by the blue squares, and the rest of the compounds are shown by the green squares. The red line indicates a 3σ level of inhibition, where σ is the standard deviation of the negative controls.

By using this assay, we carried out HTS of a library of 2556 diverse molecules, which comprised known drugs used in human therapy, natural products with undetermined biological activities, compounds in agricultural use and kinase inhibitors. The assay yielded nine different hits that displayed inhibition levels larger than three standard deviations (\>3σ) of the negative controls on the same plate ([Figure 7](#gks1292-F7){ref-type="fig"}B). Three compounds (disopyramide phosphate, oleandomycin phosphate and fosfosal) displayed increase in absorbance. This was not because of enzyme activation, but because the first two compounds were phosphate salts and because phosphate was released on rapid hydrolysis of fosfosal at the acidic pH of the MGR ([@gks1292-B43]). We performed dose--response measurements with three strong hits, suramin (7.2σ), doxorubicin (3.7σ) and ellagic acid (5.1σ) ([Figure 8](#gks1292-F8){ref-type="fig"}). These data yielded *IC*~50~ values of 6.3 ± 0.2 µM and 7.7 ± 0.5 µM for suramin and doxorubicin, respectively, indicating their potent inhibitory effects. Ellagic acid displayed approximately three-fold weaker inhibition (*IC*~50~ = 22 ± 3 µM) and was not characterized further. None of the three compounds inhibited *Mtb* PPiase as assayed separately with inorganic pyrophosphate as a substrate, indicating that these compounds are bona fide *Mtb* DnaG inhibitors (the other six hits remain to be tested for DnaG and PPiase inhibition). The dose--response curves for suramin and doxorubicin could be well modelled only by using the Hill coefficients of 2.9 ± 0.1 and 2.0 ± 0.2, respectively ([Figure 8](#gks1292-F8){ref-type="fig"}), which indicates that the target contains multiple inhibitor-binding sites ([@gks1292-B44]). Figure 8.Dose--response assays with three hit compounds from the pilot HTS, suramin, doxorubicin and ellagic acid (the chemical structures are shown as insets). The assays were performed with 1.25 µM of DNA, 110 µM of NTP and 0.5 µM of *Mtb* DnaG.

Mode of inhibition of *Mtb* DnaG by suramin and doxorubicin
-----------------------------------------------------------

We first confirmed directly that suramin and doxorubicin are potent *Mtb* DnaG inhibitors by observing their effect on the synthesis of radioactively labelled RNA products on the same DNA template at conditions similar to those of the colorimetric assay ([Figure 9](#gks1292-F9){ref-type="fig"}) and in assays with a different template DNA and with all four NTPs present in the reaction ([Figure 3](#gks1292-F3){ref-type="fig"}). To investigate the inhibitory mechanisms of suramin and doxorubicin in more detail, we measured the effect of these compounds on the steady-state accumulation of PP~i~ in the primer synthesis reaction. To determine whether suramin and doxorubicin interfere with interactions of *Mtb* DnaG with DNA, NTP or both, we performed measurements of the steady-state rate of PP~i~ release as a function of inhibitor concentration for different concentrations of DNA and NTP. One set of measurements was performed at a fixed concentration of DNA (\[DNA\] = 1.25 µM) with different concentrations of NTP ([Figure 10](#gks1292-F10){ref-type="fig"}A and C) and the other set at a fixed concentration of NTP (\[NTP\] = 110 µM) with different concentrations of DNA ([Figure 10](#gks1292-F10){ref-type="fig"}B and D). The common *y*-axis intercepts in the Lineweaver--Burk plots of these data (insets in [Figure 10](#gks1292-F10){ref-type="fig"}) show that both suramin ([Figure 10](#gks1292-F10){ref-type="fig"}A and B) and doxorubicin ([Figure 10](#gks1292-F10){ref-type="fig"}B and C) are competitive inhibitors with respect to both NTP and DNA. These data effectively contain multiple dose--response curves, which, similarly to the dose--response curves presented in the previous section, indicate the presence of multiple binding sites for both suramin and doxorubicin. To obtain the equilibrium binding constant *K*~i~ and the number of sites on *Mtb* DnaG for each inhibitor, we performed a global non-linear regression analysis of these data. We used a simple assumption of multiple non-cooperative inhibitor binding sites. In addition, we used a simple approximation of an ordered sequential mechanism of priming, where an ssDNA molecule binds free *Mtb* DnaG first followed by binding of an NTP, slow primer nucleation and its rapid elongation, incorporating *m* NTP molecules per DNA-binding event. This minimal kinetic mechanism is consistent with the observed first-order kinetics of the steady-state activity of *Mtb* DnaG with respect to NTP concentration ([Figure 6](#gks1292-F6){ref-type="fig"}F) and with other data ([Figure 10](#gks1292-F10){ref-type="fig"}); the ordered binding of DNA and NTP was previously proposed for a eukaryotic primase ([@gks1292-B45]). This analysis yields the values of the mechanistic parameters for *Mtb* DnaG: the catalytic rate constant *k*~cat,app~ = 5.7 ± 0.2 min^−1^, the effective equilibrium constants for binding of ssDNA to *Mtb* DnaG *K*~DNA~ = 24 ± 10 nM and for binding of an NTP to the primed DNA-*Mtb* DnaG complex *K*~NTP~ = 170 ± 10 µM. To obtain an independent measurement of *Mtb* DnaG affinity for ssDNA, we performed a fluorimetric assay, in which increase in fluorescence polarization of a carboxyfluorescein label on ssDNA was monitored as a function of concentration of *Mtb* DnaG ([Supplementary Figure S1](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1292/-/DC1)). This assay yields equilibrium binding constant *K*~d~ = 36 ± 16 nM, in good agreement with the *K*~DNA~ value obtained from the kinetic assays. Figure 9.Inhibition of *Mtb* DnaG activity by suramin (S) and doxorubicin (D). The assay was performed under similar optimized reaction conditions and with the same DNA template as in the HTS and visualized and quantified as described in [Figure 3](#gks1292-F3){ref-type="fig"}. Figure 10.Measurements of the steady-state rate of PPi release on primer synthesis by *Mtb* DnaG in the presence of suramin (**A** and **B**) and doxorubicin (**C** and **D**). The assays were carried out at a fixed DNA concentration of 1.25 µM as a function of concentration of NTP (A and C) and at a fixed NTP concentration of 110 µM as a function of concentration of DNA (B and D). In all panels, the data collected without inhibitor are shown as open triangles, with 1.25 µM inhibitor as open squares, 2.5 µM inhibitor as open diamonds, 5 µM inhibitor as filled circles, 10 µM inhibitor as filled squares, 20 µM inhibitor as filled diamonds and 40 µM inhibitor as filled triangles. The insets display representative Lineweaver--Burk plots of the same data.

The aforementioned value of *k*~cat,app~ is equal to the intrinsic *k*~cat~ only if the primase is completely non-processive, dissociating from DNA after incorporation of one NTP, that is, when *m* = 1. Because primases are at least somewhat processive ([@gks1292-B46],[@gks1292-B47]), this value overestimates *k*~cat~. In the other extreme, if *Mtb* DnaG rapidly incorporates on average 30 nt per DNA binding event, we obtain *k*~cat~ = *k*~cat,app~/30 = 0.19 ± 0.01 min^−1^, an underestimate of *k*~cat~. The processivity of *Mtb* DnaG and the kinetics of individual NTP incorporation steps will be investigated in detail by future studies. For suramin inhibition data, an excellent fit was obtained for a minimum of *n* = 4 binding sites on *Mtb* DnaG (binding to one of which is sufficient for inhibition), with an intrinsic equilibrium binding constant for each site of *K*~i~ = 3.2 ± 0.5 µM ([Figure 10](#gks1292-F10){ref-type="fig"}A and B). The analogous analysis of doxorubicin inhibition yielded best-fit values of *n* = 3 and *K*~i~ = 2.5 ± 0.5 µM and also an excellent agreement with the model mechanism ([Figure 10](#gks1292-F10){ref-type="fig"}C and D). The data can also be fit well to a more complex model, where three molecules of suramin or two molecules of doxorubicin bind *Mtb* DnaG with high cooperativity (see 'Materials and Methods' section). Future studies are aimed at analysing the mechanism of inhibition of *Mtb* DnaG by these inhibitors in kinetic and structural detail.

DISCUSSION
==========

Pioneering studies of bacterial primase DnaG 40 years ago ([@gks1292-B48],[@gks1292-B49]) established this enzyme as an indispensable RNA polymerase that generates primers for chromosomal DNA synthesis *in vivo*. Since these initial studies, the primase activity has been monitored either directly, by detecting primers in gel and by high-performance liquid chromatography ([@gks1292-B50]) or indirectly, by observing DNA extended from the primer by DNA polymerase or by monitoring increase in PicoGreen fluorescence on formation of an RNA--DNA hybrid ([@gks1292-B26]). The use of radioactivity and gel electrophoresis or high-performance liquid chromatography for product detection impose limitations on the extent of quantitative characterization of primases and, more importantly, on our ability to exploit primases as drug targets through HTS. This study reports a novel assay that overcomes these obstacles.

Primases are intrinsically poorly processive, likely evolved so to limit the size of primers, which serve as transient substrates for initiating DNA replication, eventually getting excised by RNase H and replaced by DNA. To observe the weak primase activity *in vitro*, other stimulatory DNA replication factors, such as replicative helicase DnaB and the ssDNA-binding protein have been commonly used. With the goal of creating an orthogonal technique for detection and quantitative measurements of primase activity, we developed a non-radioactive assay, where robust activity of DnaG was achieved without its interacting partners at conditions suitable for HTS.

As *Mtb* DnaG is an important potential therapeutic target, we chose this primase and obtained it in a highly purified monomeric form; this is the first study of a mycobacterial DnaG. For coupling the primase reaction with inorganic PPiase, we chose *Mtb* PPiase. Because of its extreme specificity to PP~i~, and not NTP, as a substrate, *Mtb* PPiase is exquisitely suitable for this assay. Being an essential enzyme itself, *Mtb* PPiase serves simultaneously as a second target in inhibitor discovery by HTS.

The only previous study of HTS to search for primase inhibitors was by researchers from Bristol-Myers Squibb Company, who reported a radioactive scintillation proximity DnaG activity assay with DnaB as an accessory factor for increasing activity of DnaG and as a coupled target ([@gks1292-B25]). As assays using radioactivity cannot be performed in most academic screening facilities, our non-radioactive assay reported here provides a new accessible route to using DnaG as an inhibitory target in HTS. A robust performance of our coupled assay is showcased by a pilot HTS of 2556 small molecules, which yielded several confirmed hits. Three of these hits, suramin, doxorubicin and ellagic acid efficiently inhibited DnaG, the first two at a high potency. Both suramin and doxorubicin ([Figure 8](#gks1292-F8){ref-type="fig"}) contain aromatic base-like structural groups; therefore, these molecules are likely to bind the primase at a primase site (or sites) that would block DNA and/or NTP binding. Suramin was previously demonstrated to act as DNA- and NTP-competitive inhibitor of human DNA polymerase α and primase, respectively ([@gks1292-B51]). Owing to its polyanionic character, suramin may interact with some of the same sites on DnaG that contact phosphate groups of the DNA backbone or incoming NTP. Quantitative analysis of inhibition by suramin and doxorubicin in this study shows that both molecules apparently compete with both DNA and NTP. We considered a simple model, where ssDNA must bind DnaG first, followed by NTP for productive RNA synthesis, similarly to the ordered binding proposed for the eukaryotic primase ([@gks1292-B45]). In the framework of this model, the observed inhibitor competition with both DNA and NTP for binding the primase is interpreted as inhibitor binding to *Mtb* DnaG to block DNA binding. A more complex model where either DNA or NTP can bind free DnaG on the pathway to nucleotide transfer is also consistent with the data, and such a model is expected to yield similar *K*~i~ values. In fact, either NTP or DNA can bind to free bacterial, phage and eukaryotic primases ([@gks1292-B39],[@gks1292-B40],[@gks1292-B52]), although NTP binding *per se* need not lead to nucleotide transfer. In any case, because this more complex model contains too many fitting parameters to be resolved by the data, it was not used in the analysis. Further studies by this and other assays are needed to clarify the order of NTP and DNA binding. Another interesting observation is that the dependence of the steady-state activity of *Mtb* DnaG on inhibitor concentration indicates binding of multiple inhibitor molecules (four for suramin and three for doxorubicin, given the absence of cooperativity). The same intrinsic affinity is assumed for each subsequent binding event for simplicity, to keep the number of fitting parameters to a minimum. Even though this is an oversimplification, the low-µM effective *K*~i~ values and a complex stoichiometry are model-independent observations. NTP equilibrium binding constants for *Mtb* DnaG obtained from this analysis are comparable with those previously reported for other primases ([@gks1292-B55],[@gks1292-B56]). Equilibrium constants for primase binding to DNA, similarly to other DNA-binding proteins, likely strongly depend on the concentration of salt and the nature of the anion ([@gks1292-B42],[@gks1292-B57],[@gks1292-B58]); therefore, they are more difficult to compare. As expected for the highly optimized conditions of the assay, the *K*~d~ value for *Mtb* DnaG binding to ssDNA reported here is in the lower range of values reported for primases. For example, *E. coli* DnaG binds ssDNA with affinity of 720 nM ([@gks1292-B17]), whereas *S. aureus* DnaG binds ssDNA with a six-fold greater affinity, 112 nM \[as measured by the same group ([@gks1292-B50])\], which is only three-fold weaker than that of *Mtb* DnaG. The *K*~d~ value that we obtained for *Mtb* DnaG is similar to the recently reported affinity (34 ± 5 nM) of *Bacillus anthracis* DnaG for an ssDNA oligomer of a similar size ([@gks1292-B19]) and to the DNA-binding affinity of eukaryotic primases ([@gks1292-B45]). These measurements underscore the applicability of our assay to quantitative kinetic and thermodynamic studies of primases.

In summary, the discovery of potent *Mtb* DnaG inhibitors serves as a validation of the robust assay performance in HTS. We expect that our novel assay will find applications in basic characterization of not only primases but also other inefficient nucleic acid polymerases and pave the way to a more facile HTS discovery of potent primase inhibitors. Discovery of such compounds will certainly be useful in development of clinically useful agents.
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